Status:
RECRUITING
Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Pancreatic Cancer Non-resectable
Tumor Pancreas
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainsta...
Eligibility Criteria
Inclusion
- Age \>= 18 years old
- Diagnosed to have inoperable pancreatic cancer
- Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
- Karnofsky performance status \>= 60
- Planned for EUS examination and/or biopsy of the pancreatic tumor
Exclusion
- Allergy to bupivacaine, or alcohol
- Potentially operable after neoadjuvant therapy
- Expected survival of less than 3 months
- Patient who is already on opioids for pain control
- Previous percutaneous or EUS-guided CGN/ CPN
- Recurrent pancreatic tumors after operation
- Uncorrectable coagulopathy
- Inability or unwillingness to provide informed consent
Key Trial Info
Start Date :
November 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT06160323
Start Date
November 10 2023
End Date
July 31 2027
Last Update
December 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, Hong Kong, 00000